Noctrix Health generating $24M annual revenue from restless legs syndrome neurostimulation — commercial BCI milestone
Summary
Peripheral nerve stimulation company Noctrix Health is reportedly generating approximately $24 million per year in revenue from the Nox-T3 wearable device for restless legs syndrome, according to analyst estimates discussed in Neurotech Notables. This makes Noctrix one of the few neurotech device startups with meaningful commercial revenue outside the established Big MedTech neuromodulation platforms. The company's commercial success has attracted acquisition interest, reflecting the broader M&A activity in neuromodulation following Boston Scientific's Penumbra deal.
Why it matters
Twenty-four million dollars in annual revenue from a wearable peripheral nerve stimulator for RLS demonstrates that non-invasive neuromodulation for common neurological conditions can reach commercial scale. Most neurotech discussions focus on invasive BCIs for rare, severe conditions — Noctrix proves the business case for non-invasive devices targeting the far larger population of patients with common, chronic conditions like RLS.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial